Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.
2.

HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.

Koff WC.

Vaccine. 2012 Jun 19;30(29):4310-5. doi: 10.1016/j.vaccine.2011.11.014. Epub 2011 Nov 17. Review.

PMID:
22100891
3.

Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire.

Parsons MS, Rouleau D, Routy JP, LeBlanc R, Grant MD, Bernard NF.

AIDS. 2011 Jun 19;25(10):1249-64. doi: 10.1097/QAD.0b013e328347f9fa.

PMID:
21516028
4.

The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development.

Zhang Y, Yuan T, Li J, Zhang Y, Xu J, Shao Y, Chen Z, Zhang MY.

AIDS. 2013 Oct 23;27(16):2529-39. doi: 10.1097/QAD.0000000000000015.

5.

AIDS/HIV. Converging on an HIV vaccine.

Korber B, Gnanakaran S.

Science. 2011 Sep 16;333(6049):1589-90. doi: 10.1126/science.1211919. No abstract available.

PMID:
21921189
6.
7.

AIDS research. Novel antibody response may explain HIV vaccine success.

Cohen J.

Science. 2011 Sep 16;333(6049):1560. doi: 10.1126/science.333.6049.1560. No abstract available.

PMID:
21921167
8.

Broadly neutralizing antibodies and their significance for HIV-1 vaccines.

González N, Alvarez A, Alcamí J.

Curr HIV Res. 2010 Dec;8(8):602-12. Review.

PMID:
21054253
9.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

10.

Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).

Bao MJ, Geng WQ, Cui HL, Zhang XL, Xu DB, Nian H, Dai D, Wang YN, Shang H.

Mol Med Rep. 2012 May;5(5):1311-7. doi: 10.3892/mmr.2012.790. Epub 2012 Feb 14.

PMID:
22344547
11.

Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes.

Luo XM, Maarschalk E, O'Connell RM, Wang P, Yang L, Baltimore D.

Blood. 2009 Feb 12;113(7):1422-31. doi: 10.1182/blood-2008-09-177139. Epub 2008 Dec 4.

12.

What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?

Jülg B, Goebel FD.

Infection. 2005 Oct;33(5-6):405-7.

PMID:
16258878
13.

Defining the protective antibody response for HIV-1.

Mascola JR.

Curr Mol Med. 2003 May;3(3):209-16. Review.

PMID:
12699358
14.

Specificities of broadly neutralizing anti-HIV-1 sera.

Binley J.

Curr Opin HIV AIDS. 2009 Sep;4(5):364-72. doi: 10.1097/COH.0b013e32832e06fe. Review.

PMID:
20048699
15.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

16.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
17.

Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.

Srivastava IK, Ulmer JB, Barnett SW.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S33-52. Review.

PMID:
15285704
18.

Neutralizing antibodies against HIV -- back in the major leagues?

Ferrantelli F, Ruprecht RM.

Curr Opin Immunol. 2002 Aug;14(4):495-502. Review.

PMID:
12088685
19.

Infectious disease. An enterprising time for HIV vaccine research.

Cohen J.

Science. 2012 Sep 21;337(6101):1446. No abstract available. Erratum in: Science. 2012 Nov 9;338(6108):742.

PMID:
22997300
20.

Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection.

Ciupe SM, De Leenheer P, Kepler TB.

J Theor Biol. 2011 May 21;277(1):55-66. doi: 10.1016/j.jtbi.2011.01.050. Epub 2011 Feb 16.

PMID:
21315731

Supplemental Content

Support Center